Evidence Behind Treatment of Asymptomatic Hyperuricaemia: A Narrative Review

Abstract

Background: Asymptomatic hyperuricaemia is frequently detected during assessment of metabolic and kidney disease. Although elevated serum urate is associated with adverse health outcomes, the value of pharmacological treatment in the absence of gout remains uncertain.Objective: To critically review the rationale, clinical efficacy, safety, and guideline implications of urate-lowering therapy in adults with asymptomatic hyperuricaemia.Review approach: A focused narrative synthesis of selected mechanistic studies, clinical trials, and practice guidelines was undertaken. Evidence was organised by biochemical response, kidney outcomes, cardiovascular outcomes, and prevention of gout. Studies involving established gout or diabetes were considered separately where their applicability to asymptomatic hyperuricaemia was indirect. No quantitative pooling was performed.Evidence synthesis: Allopurinol and febuxostat reliably reduce serum urate. However, CKD-FIX, PERL, and FEATHER did not demonstrate overall protection against kidney function decline in their respective populations. Earlier favourable studies largely assessed surrogate outcomes or smaller samples. CARES and FAST provide differing cardiovascular safety findings in patients with gout and do not establish a preventive indication in asymptomatic individuals. Treatment decisions must therefore distinguish laboratory improvement from patient-important benefit.Conclusion: Routine pharmacological treatment of isolated asymptomatic hyperuricaemia is not supported by consistent evidence of kidney or cardiovascular benefit. Management should emphasise assessment of underlying causes, established treatment of comorbid disease, and appropriate follow-up. Further trials are needed to define whether carefully selected subgroups benefit from intervention.